• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Adenocarcinoma, Mucinous

Adenocarcinoma, Mucinous - 21 Studies Found

Completed : CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
:
  • Mucinous Adenocarcinoma of the Colon
  • Muci
    : 2014-09-02
    :
    • Drug: 6,8-bis(benzylthio)octanoic acid

Active, not recruiting : Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
:
  • Mucinous Adenocarcinoma of the Colon
  • Muci
    : 2013-08-13
    :
    • Drug: irinotecan hydrochloride

Recruiting : Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
:
  • Mucinous Adenocarcinoma of the Colon
  • Muci
    : 2013-02-25
    :
    • Biological: panitumumab Given

Completed : A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
:
  • Mucinous Adenocarcinoma of the Colon
  • Muci
    : 2003-05-06
    :
    • Drug: erlotinib hydrochloride

Terminated : Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
:
  • Mucinous Adenocarcinoma of the Colon
  • Muci
    : 1999-11-01
    :
    • Drug: fluorouracil Given IV

Terminated : Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
:
  • Adenocarcinoma of the Colon
  • Adenocarcinoma of the Rectum
  • <
    : 2003-01-24
    :
    • Drug: irinotecan hydrochloride

Active, not recruiting : Low Rectal Cancer Study (MERCURY II)
:
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Colon Mucinous Adenocarcinoma
  • Colon Signet Ring Cell Adenocarci
    : 2013-02-27
    :
    • Drug: Akt Inhibitor MK2206 Giv

Terminated : Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
:
  • Colon Mucinous Adenocarcinoma
  • Colon Signet Ring Cell Adenocarci
    : 2010-09-09
    :
    • Biological: Cetuximab Given IV

Active, not recruiting : Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
:
  • Borderline Ovarian Mucinous Tumor
  • Ovarian Mucinous Cystadenocarcinoma<
    : 2010-03-04
    :
    • Biological: Bevacizumab Given

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.